Press coverage about LeMaitre Vascular (NASDAQ:LMAT) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. LeMaitre Vascular earned a news impact score of 0.10 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.3167274313017 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of LeMaitre Vascular (NASDAQ:LMAT) traded up $0.68 during midday trading on Friday, hitting $32.64. 107,788 shares of the stock traded hands, compared to its average volume of 109,071. The stock has a market cap of $628.81, a PE ratio of 42.39, a price-to-earnings-growth ratio of 2.51 and a beta of 0.54. LeMaitre Vascular has a 52-week low of $19.82 and a 52-week high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.05. The firm had revenue of $24.80 million for the quarter, compared to analysts’ expectations of $25.49 million. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 EPS. equities research analysts predict that LeMaitre Vascular will post 0.84 earnings per share for the current fiscal year.
In related news, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $32.14, for a total transaction of $132,513.22. Following the transaction, the insider now directly owns 24,482 shares in the company, valued at approximately $786,851.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 23.70% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect LeMaitre Vascular (LMAT) Stock Price” was first posted by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/lemaitre-vascular-lmat-given-daily-media-impact-score-of-0-10/1808425.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with our FREE daily email newsletter.